Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...

USA: The findings from a recent retrospective cohort study involving 3,389 patients with obesity revealed the effectiveness ...

Recently, GLP-1 receptor agonist medications have been prescribed more commonly, in part due to their ability to produce ...

For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication active agent.

In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...

Four key factors can greatly impact how much weight people lose while taking GLP-1 drugs like Ozempic, Wegovy, Victoza, and ...

A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were ...